Peyronie disease
ICD-10 N48.6 · ICD-11 GB06.2

Treatment of Stable Peyronie's Disease with Palpable Dorsal Penile Plaques

This page addresses the structured management of stable Peyronie's disease presenting with palpable, non-calcified dorsal penile plaques and dorsal or lateral curvature of 30–90°, in patients without erectile dysfunction refractory to pharmacotherapy.

Clinical Scenario

Treatment Approach

For this presentation, the evidence-based approach involves intralesional collagenase clostridium histolyticum delivered in structured injection cycles. Mechanical adjunct therapies may be incorporated as part of a multimodal strategy.

The complete cycle structure, protocol variants, injection schedules, and mechanical adjunct details are available in the full structured protocol.

Treatment Goals

Instant Access to Structured Evidence-Based Regimens

References

  1. Use intralesional therapy with collagenase clostridium histolyticum in patients with PD and dorsal or lateral curvature > 30˚, who request non-surgical treatment.
  2. In 2014, the EMA-approved CCH for the non-surgical treatment of the stable phase of PD in men with palpable dorsal plaques in whom abnormal curvature of 30-90° and non-ventrally located plaques are present.
  3. The original treatment protocol in all studies consists of two injections of 0.58mg of CCH 24-72 hours apart every six weeks for up to four cycles.
  4. A modified short protocol consisting of administration of a single (0.9mg, one vial) injection per cycle distributed along three lines around the point of maximum curvature up to three cycles, separated by four-weekly intervals, has been proposed and rapidly popularised replacing physician modelling with a multi-modal approach through penile stretching, modelling and VED at home.
  5. Offer penile traction devices and vacuum devices to reduce penile deformity or as part of a multimodal therapy approach, although outcome data is limited.
  6. Intralesional treatment with collagenase clostridium histolyticum showed significant decreases in penile curvature, plaque diameter and plaque length in men with acute and stable disease.
View source ↗